Heart device company Biotronik says the U.S. FDA has approved its Entovis pacemaker system with ProMRI® technology. The Entovis system allows patients to undergo Magnetic Resonance Imaging (MRI) scans with a limited exclusion zone. FDA approval covers both single chamber (SR-T) and dual chamber (DR-T) Entovis pacemakers when implanted with Setrox pacing leads.
Approximately 50,000 single-chamber pacemakers are currently implanted in the U.S. each year. Until now, these patients have not been able to access MRI scans because the strong forces applied have been shown to have a negative effect on pacing systems.
The FDA approval is based on clinical study findings, coming only 16 months after the initial clinical study was launched, and five months after the approval of that study’s expansion to include full-body MRI scans. These studies were designed to assess the safety and efficacy of Biotronik’s existing single- and dual-chamber Entovis pacemaker systems and Setrox 53 and 60cm leads during MRI scans. These devices, while already commercially available in the U.S., lacked FDA approval for use in the MRI environment until now.
With this new approval, Biotronik becomes the first company in the U.S. to offer both single- and dual-chamber pacemakers approved for use in an MRI environment. It is also the first company worldwide to offer the current generation of pacing leads with ProMRI® pacemakers. Setrox, including versions released under other names, is the most used lead in MRI pacemakers on the market today with over 850,000 leads sold worldwide.
Biotronik says the Entovis system presents advantages over existing pacemakers approved as MR conditional. Patients with approved Entovis pacemakers and leads need only alert radiology staff of their device and the staff will verify the patient meets the criteria to undergo an MRI scan.
“With the Entovis longevity and the history of lead reliability, this is a system that will serve a wide variety of pacemaker patients for the foreseeable—and unforeseen—future needs,” said Carleton Nibley, M.D., electrophysiologist at John Muir Medical Center in Concord and Walnut Creek, California, and a participant in the ProMRI® study.
“The Biotronik Entovis ProMRI® pacemaker system is the latest example of our commitment to excellence and meaningful innovation in supporting patient treatment and quality of life,” said Paul Woodstock, Biotronik Executive Vice President of Sales and Marketing. “We are proud to be able to satisfy the demand for state-of-the-art devices that allow physicians to deliver optimal care to the increasing number of pacemaker patients who may someday need an MRI.”